Despite the emergence of new pharmacologic alternatives to traditional bariatric surgery, the global obesity epidemic continues to escalate. Semaglutides, while effective for some, are costly, require weekly injections, and often cause side effects that lead many patients to discontinue treatment and subsequently regain much or all of the weight they lost. Both bypass and restrictive bariatric procedures carry significant risks, side effects, and long-term lifestyle adjustments, and most patients ultimately reach a weight-loss plateau. Endoscopic visceral lipectomy, though not yet clinically validated or widely adopted, offers the potential for a more permanent solution one that might help patients achieve a lower, more sustainable weight plateau without the same tradeoffs. Clinicians can work together to tailor combinations of pharmacologic and surgical strategies to best support the health of individual patients. Earlier intervention may help future generations.
Continued development of new medications and research into alternative surgical approaches should be encouraged. However, the widespread availability of highly addictive, calorie-dense, nutrient-poor junk and ultra-processed foods-paired with increasingly sedentary lifestyles and the pervasive use of addictive social media-continues to drive the epidemic beyond our current capacity to control it. Meaningful progress will require coordinated efforts among governments, schools, and food manufacturers to improve labeling, reduce the caloric density of snack foods, promote physical activity, limit screen time, decrease youth exposure to junk-food advertising, and foster healthier eating and exercise habits. A fuller discussion of the critical question of when-and how early-we should intervene to reverse the tightening spiral of obesity found in a recent article: The Next Frontier in Obesity and Type 2 Diabetes Treatment: Permanent Minimally Invasive Visceral Fat Removal and the Emerging Role of Early Intervention. R. L. Cucin OAJS 17:555952 (2025)